Joao vitor Bizinotto Lana 1*, Napoliane Santos 2,3, Gregory Melo1, Gabriel Silva Santos 2,3, Palmerindo Mendonca 2,3, Luyddy Pires 2,3, Francisco Honorio 2,3, Lucas Furtado da Fonseca 2,3,4, Raffael Marum Bachir 3,5, Rafael Barnabe Do
Achilles tendon rupture is a frequent ailment tied to overuse injuries of the ankle and foot. Given the tendon's limited vascularization, which depends on diffusion from synovial fluid for nutrient intake, managing this condition poses challenges. The weakened state post-rupture can predispose one to further injuries. Although surgical interventions often lead the way in treatment, challenges can arise during recovery. Meanwhile, the use of orthobiologics for non-invasive treatment has shown promising outcomes in various regenerative medicine applications. Notably, autologous treatments like bone marrow aspirate (BMA) and injectable platelet-rich fibrin (i-PRF) have gained traction in clinical scenarios.
BMA is a reservoir of diverse cell populations and molecules pivotal for tissue regeneration. PRF, on the other hand, is a dense concoction of platelets, growth factors, cytokines, leukocytes, and a sturdy fibrin matrix conducive to cellular functions.
Utilizing a combination of these two orthobiologic entities could amplify their individual effects, optimizing the healing process by fostering tissue growth, fostering new blood vessel formation, and modulating immune responses.
With this understanding, we advocate for the joint use of BMA and i-PRF as a potent orthobiologic solution, aiming to improve the healing trajectory of Achilles tendon ruptures within the sphere of regenerative orthopedics.
English 
Spanish 
Chinese 
German 
French 
Japanese 
Portuguese 
Hindi